ixazomib
Showing 1 - 25 of 76
Relapsed and Refractory Multiple Myeloma Trial in Pittsburgh (Mezigdomide, Ixazomib, Dexamethasone)
Not yet recruiting
- Relapsed and Refractory Multiple Myeloma
- Mezigdomide
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Sep 15, 2023
Multiple Myeloma Trial in Hangzhou (Ixazomib plus low-dose lenalidomide, Ixazomib)
Recruiting
- Multiple Myeloma
- Ixazomib plus low-dose lenalidomide
- Ixazomib
-
Hangzhou, Zhejiang, ChinaYang Xu
Feb 9, 2023
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Atlanta, Ann Arbor, Saint Louis (Dexamethasone, Ixazomib,
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Dexamethasone
- +2 more
-
Atlanta, Georgia
- +3 more
Jan 6, 2023
Plasma Cell Myeloma Trial in Atlanta (Bortezomib, Daratumumab, Dexamethasone)
Active, not recruiting
- Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Jan 10, 2023
Multiple Myeloma Trial in United States (Ixazomib, Lenalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Ixazomib
- +2 more
-
Duarte, California
- +9 more
Jan 11, 2023
Metastatic Kidney Medullary Carcinoma, Metastatic Renal Cell Carcinoma, SMARCB1 Negative Trial in Houston (Doxorubicin,
Recruiting
- Metastatic Kidney Medullary Carcinoma
- +4 more
- Doxorubicin
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Jan 20, 2023
Mantle-Cell Lymphoma Trial in United States (Ixazomib, Ibrutinib)
Active, not recruiting
- Mantle-Cell Lymphoma
- Ixazomib
- Ibrutinib
-
Atlanta, Georgia
- +13 more
Nov 17, 2022
Multiple Myeloma Trial in Pawtucket, Providence (Ixazomib, Cyclophosphamide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Ixazomib
- +2 more
-
Pawtucket, Rhode Island
- +2 more
Jul 21, 2022
Mantle Cell Lymphoma Trial in Busan (Ixazomib)
Recruiting
- Mantle Cell Lymphoma
- Ixazomib
-
Busan, Western, Korea, Republic ofKosin University Gospel Hospital
Mar 31, 2022
Multiple Myeloma, Multiple Myeloma in Relapse Trial in Boston (Ixazomib, Pomalidomide, Dexamethasone)
Recruiting
- Multiple Myeloma
- Multiple Myeloma in Relapse
- Ixazomib
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Apr 13, 2022
Smoldering Multiple Myeloma Trial in Boston (Ixazomib, Lenalidomide, Dexamethasone)
Active, not recruiting
- Smoldering Multiple Myeloma
- Ixazomib
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Mar 15, 2022
AML, AML, Adult Trial in Indianapolis (TAK-659, Ixazomib)
Terminated
- AML
- AML, Adult
- TAK-659
- Ixazomib
-
Indianapolis, IndianaIndiana University Melvin and Bren Simon Cancer Center
Mar 15, 2022
Relapsed/Refractory Multiple Myeloma Trial in La Jolla (Ixazomib, Pomalidomide, Dexamethasone)
Recruiting
- Relapsed/Refractory Multiple Myeloma
- Ixazomib
- +3 more
-
La Jolla, CaliforniaUCSD Moores Cancer Center
Mar 7, 2022
Hematopoietic Stem Cell Transplantation, Multiple Myeloma Trial in Spain (Ixazomib, Tacrolimus, Sirolimus)
Recruiting
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma
- Ixazomib
- +3 more
-
Badalona, Spain
- +7 more
May 20, 2022
Systemic Sclerosis, Scleroderma, Diffuse Systemic Sclerosis Trial in Scottsdale (Ixazomib)
Recruiting
- Systemic Sclerosis
- +18 more
- Ixazomib
-
Scottsdale, ArizonaMayo Clinic in Arizona
May 3, 2022
Relapsed and/or Refractory Multiple Myeloma Trial in Japan (Ixazomib, Bortezomib, Carfilzomib)
Completed
- Relapsed and/or Refractory Multiple Myeloma
- Ixazomib
- +4 more
-
Kamogawa, Chiba, Japan
- +22 more
Jul 27, 2022
ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood Trial in Australia, United States
Recruiting
- ALL, Childhood
- +2 more
- Ixazomib
- +7 more
-
Los Angeles, California
- +17 more
Aug 11, 2022
Mantle Cell Lymphoma Trial in Atlanta (Ixazomib, Rituximab)
Active, not recruiting
- Mantle Cell Lymphoma
- Ixazomib
- Rituximab
-
Atlanta, Georgia
- +1 more
Oct 26, 2021
Multiple Myeloma Trial in Worldwide (Ixazomib, Lenalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Ixazomib
- +2 more
-
Helsinki, Finland
- +25 more
Mar 14, 2022
Newly Diagnosed Multiple Myeloma Trial in New York (Daratumumab, Bortezomib, Lenalidomide)
Recruiting
- Newly Diagnosed Multiple Myeloma
- Daratumumab
- +4 more
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Dec 29, 2022
Multiple Myeloma at First Relapse Trial in France (Ixazomib, Iberdomide, Dexamethasone Oral)
Recruiting
- Multiple Myeloma at First Relapse
- Ixazomib
- +2 more
-
Annecy, France
- +20 more
Dec 16, 2021
Myeloid Hematologic Malignancy, Lymphoid Hematologic Malignancy Trial in New York (Ixazomib)
Completed
- Myeloid Hematologic Malignancy
- Lymphoid Hematologic Malignancy
- Ixazomib
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Sep 3, 2021